[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fvOhzPKNVCWOwHzP4f8aCMLJUIwYFAOo8VECefPTVLDk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Deutsches Herzzentrum Muenchen",[4],114,false,11,2,82822,0,92,[14,17,20,22,24,26,29,32],{"name":15,"count":16},"Atrial Fibrillation",14,{"name":18,"count":19},"Coronary Disease",12,{"name":21,"count":19},"Coronary Artery Disease",{"name":23,"count":8},"Coronary Heart Disease",{"name":25,"count":8},"Myocardial Infarction",{"name":27,"count":28},"Acute Coronary Syndrome",4,{"name":30,"count":31},"Electromagnetic Interference",3,{"name":33,"count":31},"Congenital Heart Disease",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,103,151,177,218,251,273,307,329,351,370,396,421,439,464,482,510,528,552,570,591,615,642,660],{"intervention":44,"totalTrials":28,"cells":45},"Clopidogrel",{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":52,"PHASE4":54,"NA":101},{"trials":47,"activeCount":11},[],{"trials":49,"activeCount":11},[],{"trials":51,"activeCount":11},[],{"trials":53,"activeCount":11},[],{"trials":55,"activeCount":11},[56,70,80,89],{"nctId":57,"briefTitle":58,"status":59,"phases":60,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":65,"interventions":66},"NCT00976092","Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial Infarction","UNKNOWN",[40],"2014-02","2015-02","2009-09",548,[25],[67,68,44,69],"Prasugrel","Bivalirudin","Heparin",{"nctId":71,"briefTitle":72,"status":73,"phases":74,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":79},"NCT00140465","75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)","COMPLETED",[40],"2005-07","2004-10",60,[18],[44,44],{"nctId":81,"briefTitle":82,"status":59,"phases":83,"primaryCompletion":84,"completion":84,"start":85,"enrollment":86,"conditions":87,"interventions":88},"NCT00661206","Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting",[40],"2014-11","2008-09",4005,[21],[44],{"nctId":90,"briefTitle":91,"status":59,"phases":92,"primaryCompletion":93,"completion":94,"start":85,"enrollment":95,"conditions":96,"interventions":97},"NCT00776633","Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation",[40],"2013-12","2014-09",614,[21,15],[98,99,100],"aspirin","clopidogrel","oral anticoagulation",{"trials":102,"activeCount":11},[],{"intervention":104,"totalTrials":31,"cells":105},"Ticagrelor",{"EARLY_PHASE1":106,"PHASE1":108,"PHASE2":110,"PHASE3":112,"PHASE4":126,"NA":149},{"trials":107,"activeCount":11},[],{"trials":109,"activeCount":11},[],{"trials":111,"activeCount":11},[],{"trials":113,"activeCount":11},[114],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":124},"NCT01755520","Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG","TERMINATED",[39],"2018-05-19","2013-04-24",1893,[21,123,27],"Stable Angina",[104,125],"Aspirin",{"trials":127,"activeCount":11},[128,138],{"nctId":129,"briefTitle":130,"status":59,"phases":131,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":137},"NCT01456364","Intracoronary Stenting and Antithrombotic Regimen: ADjusting Antiplatelet Treatment in PatienTs Based on Platelet Function Testing",[40],"2014-04","2014-05","2011-09",70,[23],[104,67],{"nctId":139,"briefTitle":140,"status":73,"phases":141,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":146,"interventions":148},"NCT01944800","Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome",[40],"2019-07","2021-09","2013-09-15",4018,[147],"Acute Coronary Syndrome (ACS)",[104,67],{"trials":150,"activeCount":11},[],{"intervention":67,"totalTrials":31,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":175},{"trials":154,"activeCount":11},[],{"trials":156,"activeCount":11},[],{"trials":158,"activeCount":11},[],{"trials":160,"activeCount":11},[],{"trials":162,"activeCount":11},[163,167,171],{"nctId":129,"briefTitle":130,"status":59,"phases":164,"primaryCompletion":132,"completion":133,"start":134,"enrollment":135,"conditions":165,"interventions":166},[40],[23],[104,67],{"nctId":139,"briefTitle":140,"status":73,"phases":168,"primaryCompletion":142,"completion":143,"start":144,"enrollment":145,"conditions":169,"interventions":170},[40],[147],[104,67],{"nctId":57,"briefTitle":58,"status":59,"phases":172,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":173,"interventions":174},[40],[25],[67,68,44,69],{"trials":176,"activeCount":11},[],{"intervention":68,"totalTrials":31,"cells":178},{"EARLY_PHASE1":179,"PHASE1":181,"PHASE2":183,"PHASE3":185,"PHASE4":187,"NA":216},{"trials":180,"activeCount":11},[],{"trials":182,"activeCount":11},[],{"trials":184,"activeCount":11},[],{"trials":186,"activeCount":11},[],{"trials":188,"activeCount":11},[189,200,204],{"nctId":190,"briefTitle":191,"status":73,"phases":192,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":197,"interventions":198},"NCT00373451","Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome",[40],"2011-05","2011-07","2006-07",1721,[25,18],[199,68,69],"Abciximab + UFH",{"nctId":57,"briefTitle":58,"status":59,"phases":201,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":202,"interventions":203},[40],[25],[67,68,44,69],{"nctId":205,"briefTitle":206,"status":73,"phases":207,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},"NCT00262054","Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)",[40],"2008-02","2008-05","2005-11",4570,[18,213],"Angina Pectoris",[68,215],"Un-fractionated heparin",{"trials":217,"activeCount":11},[],{"intervention":219,"totalTrials":9,"cells":220},"Dabigatran",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":249},{"trials":222,"activeCount":11},[],{"trials":224,"activeCount":11},[],{"trials":226,"activeCount":11},[],{"trials":228,"activeCount":11},[],{"trials":230,"activeCount":11},[231,241],{"nctId":232,"briefTitle":233,"status":73,"phases":234,"primaryCompletion":235,"completion":236,"start":237,"enrollment":135,"conditions":238,"interventions":239},"NCT01339819","Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation",[40],"2012-05","2012-09","2011-04",[15],[219,240],"Phenprocoumon",{"nctId":242,"briefTitle":243,"status":117,"phases":244,"primaryCompletion":133,"completion":133,"start":193,"enrollment":245,"conditions":246,"interventions":248},"NCT01352702","Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation",[40],46,[23,15,27,247],"Atherosclerosis",[219,240],{"trials":250,"activeCount":11},[],{"intervention":240,"totalTrials":9,"cells":252},{"EARLY_PHASE1":253,"PHASE1":255,"PHASE2":257,"PHASE3":259,"PHASE4":261,"NA":271},{"trials":254,"activeCount":11},[],{"trials":256,"activeCount":11},[],{"trials":258,"activeCount":11},[],{"trials":260,"activeCount":11},[],{"trials":262,"activeCount":11},[263,267],{"nctId":232,"briefTitle":233,"status":73,"phases":264,"primaryCompletion":235,"completion":236,"start":237,"enrollment":135,"conditions":265,"interventions":266},[40],[15],[219,240],{"nctId":242,"briefTitle":243,"status":117,"phases":268,"primaryCompletion":133,"completion":133,"start":193,"enrollment":245,"conditions":269,"interventions":270},[40],[23,15,27,247],[219,240],{"trials":272,"activeCount":11},[],{"intervention":274,"totalTrials":9,"cells":275},"Abciximab",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":305},{"trials":277,"activeCount":11},[],{"trials":279,"activeCount":11},[],{"trials":281,"activeCount":11},[],{"trials":283,"activeCount":11},[],{"trials":285,"activeCount":11},[286,296],{"nctId":287,"briefTitle":288,"status":73,"phases":289,"primaryCompletion":290,"completion":290,"start":291,"enrollment":292,"conditions":293,"interventions":295},"NCT00133003","Abciximab, Clopidogrel and Percutaneous Coronary Intervention in Acute Coronary Syndrome (ISAR-REACT-2)",[40],"2006-01","2003-03",2022,[18,294],"Angina, Unstable",[274],{"nctId":297,"briefTitle":298,"status":73,"phases":299,"primaryCompletion":208,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT00133250","Value of Abciximab in Patients With AMI Undergoing Primary PCI After Clopidogrel Pretreatment (BRAVE 3)",[40],"2008-03","2003-06",800,[25],[274],{"trials":306,"activeCount":11},[],{"intervention":125,"totalTrials":9,"cells":308},{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":321,"NA":327},{"trials":310,"activeCount":11},[],{"trials":312,"activeCount":11},[],{"trials":314,"activeCount":11},[],{"trials":316,"activeCount":11},[317],{"nctId":115,"briefTitle":116,"status":117,"phases":318,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":319,"interventions":320},[39],[21,123,27],[104,125],{"trials":322,"activeCount":11},[323],{"nctId":90,"briefTitle":91,"status":59,"phases":324,"primaryCompletion":93,"completion":94,"start":85,"enrollment":95,"conditions":325,"interventions":326},[40],[21,15],[98,99,100],{"trials":328,"activeCount":11},[],{"intervention":69,"totalTrials":9,"cells":330},{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":349},{"trials":332,"activeCount":11},[],{"trials":334,"activeCount":11},[],{"trials":336,"activeCount":11},[],{"trials":338,"activeCount":11},[],{"trials":340,"activeCount":11},[341,345],{"nctId":190,"briefTitle":191,"status":73,"phases":342,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":343,"interventions":344},[40],[25,18],[199,68,69],{"nctId":57,"briefTitle":58,"status":59,"phases":346,"primaryCompletion":61,"completion":62,"start":63,"enrollment":64,"conditions":347,"interventions":348},[40],[25],[67,68,44,69],{"trials":350,"activeCount":11},[],{"intervention":199,"totalTrials":352,"cells":353},1,{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":368},{"trials":355,"activeCount":11},[],{"trials":357,"activeCount":11},[],{"trials":359,"activeCount":11},[],{"trials":361,"activeCount":11},[],{"trials":363,"activeCount":11},[364],{"nctId":190,"briefTitle":191,"status":73,"phases":365,"primaryCompletion":193,"completion":194,"start":195,"enrollment":196,"conditions":366,"interventions":367},[40],[25,18],[199,68,69],{"trials":369,"activeCount":11},[],{"intervention":371,"totalTrials":352,"cells":372},"Sirolimus",{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":381,"NA":394},{"trials":374,"activeCount":11},[],{"trials":376,"activeCount":11},[],{"trials":378,"activeCount":11},[],{"trials":380,"activeCount":11},[],{"trials":382,"activeCount":11},[383],{"nctId":384,"briefTitle":385,"status":73,"phases":386,"primaryCompletion":387,"completion":388,"start":389,"enrollment":390,"conditions":391,"interventions":393},"NCT00859183","Oral Sirolimus for In-Stent Restenosis",[40],"2004-02","2004-03","2001-10",300,[392],"Coronary Restenosis",[371,371],{"trials":395,"activeCount":11},[],{"intervention":397,"totalTrials":352,"cells":398},"Abrupt Clopidogrel Interruption",{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":405,"PHASE4":407,"NA":419},{"trials":400,"activeCount":11},[],{"trials":402,"activeCount":11},[],{"trials":404,"activeCount":11},[],{"trials":406,"activeCount":11},[],{"trials":408,"activeCount":11},[409],{"nctId":410,"briefTitle":411,"status":117,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":416,"interventions":417},"NCT00640679","Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation",[40],"2012-08","2008-04",782,[21],[397,418],"Clopidogrel Tapering",{"trials":420,"activeCount":11},[],{"intervention":418,"totalTrials":352,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":429,"PHASE4":431,"NA":437},{"trials":424,"activeCount":11},[],{"trials":426,"activeCount":11},[],{"trials":428,"activeCount":11},[],{"trials":430,"activeCount":11},[],{"trials":432,"activeCount":11},[433],{"nctId":410,"briefTitle":411,"status":117,"phases":434,"primaryCompletion":413,"completion":413,"start":414,"enrollment":415,"conditions":435,"interventions":436},[40],[21],[397,418],{"trials":438,"activeCount":11},[],{"intervention":440,"totalTrials":352,"cells":441},"unfractionated heparin",{"EARLY_PHASE1":442,"PHASE1":444,"PHASE2":446,"PHASE3":448,"PHASE4":450,"NA":462},{"trials":443,"activeCount":11},[],{"trials":445,"activeCount":11},[],{"trials":447,"activeCount":11},[],{"trials":449,"activeCount":11},[],{"trials":451,"activeCount":11},[452],{"nctId":453,"briefTitle":454,"status":73,"phases":455,"primaryCompletion":456,"completion":457,"start":458,"enrollment":459,"conditions":460,"interventions":461},"NCT00735280","Reduced Dose of Unfractionated Heparin in Patients Undergoing PCI",[40],"2010-03","2011-03","2008-08",2505,[21],[440],{"trials":463,"activeCount":11},[],{"intervention":215,"totalTrials":352,"cells":465},{"EARLY_PHASE1":466,"PHASE1":468,"PHASE2":470,"PHASE3":472,"PHASE4":474,"NA":480},{"trials":467,"activeCount":11},[],{"trials":469,"activeCount":11},[],{"trials":471,"activeCount":11},[],{"trials":473,"activeCount":11},[],{"trials":475,"activeCount":11},[476],{"nctId":205,"briefTitle":206,"status":73,"phases":477,"primaryCompletion":208,"completion":209,"start":210,"enrollment":211,"conditions":478,"interventions":479},[40],[18,213],[68,215],{"trials":481,"activeCount":11},[],{"intervention":483,"totalTrials":352,"cells":484},"Iodixanol 320",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":508},{"trials":486,"activeCount":11},[],{"trials":488,"activeCount":11},[],{"trials":490,"activeCount":11},[],{"trials":492,"activeCount":11},[],{"trials":494,"activeCount":11},[495],{"nctId":496,"briefTitle":497,"status":73,"phases":498,"primaryCompletion":499,"completion":500,"start":195,"enrollment":501,"conditions":502,"interventions":506},"NCT00390585","Iodixanol vs. Iomeprol to Prevent Contrast-Induced Nephropathy After Coronary Intervention (CONTRAST)",[40],"2008-01","2008-12",324,[503,504,505],"Renal Insufficiency, Chronic","Angioplasty, Transluminal, Percutaneous Coronary","Coronary Arteriosclerosis",[483,507],"Iomeprol 350",{"trials":509,"activeCount":11},[],{"intervention":507,"totalTrials":352,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":526},{"trials":513,"activeCount":11},[],{"trials":515,"activeCount":11},[],{"trials":517,"activeCount":11},[],{"trials":519,"activeCount":11},[],{"trials":521,"activeCount":11},[522],{"nctId":496,"briefTitle":497,"status":73,"phases":523,"primaryCompletion":499,"completion":500,"start":195,"enrollment":501,"conditions":524,"interventions":525},[40],[503,504,505],[483,507],{"trials":527,"activeCount":11},[],{"intervention":529,"totalTrials":352,"cells":530},"ORSIRO",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":550},{"trials":532,"activeCount":11},[],{"trials":534,"activeCount":11},[],{"trials":536,"activeCount":11},[],{"trials":538,"activeCount":11},[],{"trials":540,"activeCount":11},[541],{"nctId":542,"briefTitle":543,"status":73,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":547,"conditions":548,"interventions":549},"NCT01594736","ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography",[40],"2013-06","2012-04",30,[23],[529],{"trials":551,"activeCount":11},[],{"intervention":100,"totalTrials":352,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":11},[],{"trials":557,"activeCount":11},[],{"trials":559,"activeCount":11},[],{"trials":561,"activeCount":11},[],{"trials":563,"activeCount":11},[564],{"nctId":90,"briefTitle":91,"status":59,"phases":565,"primaryCompletion":93,"completion":94,"start":85,"enrollment":95,"conditions":566,"interventions":567},[40],[21,15],[98,99,100],{"trials":569,"activeCount":11},[],{"intervention":571,"totalTrials":352,"cells":572},"G-CSF Granulocyte-Colony Stimulating Factor",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":589},{"trials":574,"activeCount":11},[],{"trials":576,"activeCount":11},[],{"trials":578,"activeCount":11},[],{"trials":580,"activeCount":11},[],{"trials":582,"activeCount":11},[583],{"nctId":584,"briefTitle":585,"status":73,"phases":586,"completion":75,"start":387,"enrollment":6,"conditions":587,"interventions":588},"NCT00126100","Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2)",[40],[25],[571],{"trials":590,"activeCount":11},[],{"intervention":592,"totalTrials":352,"cells":593},"Erythropoietin",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":611,"NA":613},{"trials":595,"activeCount":11},[],{"trials":597,"activeCount":11},[],{"trials":599,"activeCount":11},[],{"trials":601,"activeCount":11},[602],{"nctId":603,"briefTitle":604,"status":73,"phases":605,"primaryCompletion":606,"completion":606,"start":607,"enrollment":608,"conditions":609,"interventions":610},"NCT00390832","Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)",[39],"2009-03","2006-12",138,[25,504],[592],{"trials":612,"activeCount":11},[],{"trials":614,"activeCount":11},[],{"intervention":616,"totalTrials":352,"cells":617},"Revacept 80 mg",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":619,"activeCount":11},[],{"trials":621,"activeCount":11},[],{"trials":623,"activeCount":11},[624],{"nctId":625,"briefTitle":626,"status":73,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":634},"NCT03312855","Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept",[38],"2020-02-29","2020-03-26","2017-11-20",334,[633],"Stable Coronary Artery Disease",[616,635],"Revacept 160 mg",{"trials":637,"activeCount":11},[],{"trials":639,"activeCount":11},[],{"trials":641,"activeCount":11},[],{"intervention":635,"totalTrials":352,"cells":643},{"EARLY_PHASE1":644,"PHASE1":646,"PHASE2":648,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":645,"activeCount":11},[],{"trials":647,"activeCount":11},[],{"trials":649,"activeCount":11},[650],{"nctId":625,"briefTitle":626,"status":73,"phases":651,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":652,"interventions":653},[38],[633],[616,635],{"trials":655,"activeCount":11},[],{"trials":657,"activeCount":11},[],{"trials":659,"activeCount":11},[],{"intervention":661,"totalTrials":352,"cells":662},"Pacemaker and defibrillator",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":664,"activeCount":11},[],{"trials":666,"activeCount":11},[],{"trials":668,"activeCount":11},[],{"trials":670,"activeCount":11},[],{"trials":672,"activeCount":11},[],{"trials":674,"activeCount":11},[675],{"nctId":676,"briefTitle":677,"status":73,"phases":678,"primaryCompletion":679,"completion":680,"start":681,"enrollment":390,"conditions":682,"interventions":684},"NCT01819896","Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices",[],"2013-10","2015-01","2013-02",[683],"Recipients of Implantable Pacemakers or Defibrillators",[661]]